Compare Citius Pharmaceuticals Inc (CTXR) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.4. Which is the better fit depends on your goals.
| CTXR | YMAG | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $1.82 | $15.98 |
52-Week Low | $0.48 | $10.76 |
Enterprise Value | $16.23M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
